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Abstract
The Facioscapulohumeral Muscular Dystrophy (FSHD) is an autosomal dominant neuromuscular disorder whose incidence is
estimated in about one in 400,000 to one in 20,000. No effective therapeutic strategies are known to halt progression or
reverse muscle weakness and atrophy. It is known that the FSHD is caused by modifications located within a D4ZA repeat
array in the chromosome 4q, while recent advances have linked these modifications to the DUX4 gene. Unfortunately, the
complete mechanisms responsible for the molecular pathogenesis and progressive muscle weakness still remain unknown.
Although there are many studies addressing cancer databases from a machine learning perspective, there is no such
precedent in the analysis of the FSHD. This study aims to fill this gap by analyzing two specific FSHD databases. A feature
selection algorithm is used as the main engine to select genes promoting the highest possible classification capacity. The
combination of feature selection and classification aims at obtaining simple models (in terms of very low numbers of genes)
capable of good generalization, that may be associated with the disease. We show that the reported method is highly
efficient in finding genes to discern between healthy cases (not affected by the FSHD) and FSHD cases, allowing the
discovery of very parsimonious models that yield negligible repeated cross-validation error. These models in turn give rise
to very simple decision procedures in the form of a decision tree. Current biological evidence regarding these genes shows
that they are linked to skeletal muscle processes concerning specific human conditions.
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Introduction
The Facioscapulohumeral Muscular Dystrophy (FSHD) is an
autosomal dominant neuromuscular disorder and the third most
common inherited muscular dystrophy [1,2]. Its incidence may
vary in different places and probably in different racial groups, but
recent estimates account for one in about 400,000 to one in 20,000
[3]. FSHD patients show progressive weakening and atrophy of
the muscles in the face, slowly progressing to the shoulder, upper
arm muscles and shoulder girdle, down to the stomach and lower
limbs. Inability to flex the foot upward, foot weakness, and an
onset of right/left asymmetry are also common symptoms [4,5].
Although the FSHD is considered a relatively benign dystrophy,
about 20% of the patients presenting this disorder are eventually
restrained to a wheel chair. The age of onset is variable, being the
second decade of life the most common stage where patients
become symptomatic. In some cases, however, symptoms never
develop even when the individual has the mutation associated with
the FSHD.
No effective therapeutic strategies are known to either halt
progression or reverse muscle weakness and atrophy in the FSHD
[6]. However, there are a number of actions that can provide
symptomatic and functional improvement in many patients. In
particular, the use of assistive devices –such as braces, standing
frames, or walkers– is of great help. Physical therapies like
exercises in water, complemented by psychological support and
speech therapy may also alleviate specially difficult life conditions.
It is known that the FSHD is caused by deletion of a subset
of D4Z4 macrosatellite repeat units in the subtelomere of
chromosome 4q [7]. D4Z4 modification needs to occur on a
specific chromosomic background to cause the FSHD. More
than 95% of patients with clinical FSHD have an associated
D4Z4 deletion on the 4q35 chromosome. However, a small
number of kindreds with clinically typical FSHD do not present
this dynamic. A second FSHD locus has not yet been identified
[8]. Recent advances involve the DUX4 gene, a retrogene
sequence within D4Z4 that encodes a double homeodomain
protein whose exact function is not entirely known. Although
the proper mechanisms responsible for the progressive muscle
weakness still remain unknown, the study of this gene could
offer a possible therapeutic way [7].
It is generally believed that the monitoring of expression levels
for thousands of genes simultaneously may lead to a more
complete understanding of the molecular variations among
different cell conditions. In the literature on machine learning,
contributions concerning the analysis of gene expression FSHD
data are very scarce, probably because of unawareness towards the
highly rare diseases. The situation is aggravated by the absence of
scientific data outside purely medical domains, in order to attack
the problem from a different point of view. In contrast, there is
now a vast body of available datasets about microarray gene
expression analysis when focused to cancer diseases. Specifically,
microarray gene expression databases have been used to
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discriminate between tumours or tumour subtypes, and to study
biological properties of tumours –see, e.g., [9].
Over the last decade, Machine Learning (ML) has made
significant inroads in the fields of bioinformatics and biomedicine
[10]. Specifically, cancer research has applied a variety of ML
algorithms for tumor prediction by associating expression patterns
with clinical outcomes for patients with tumors [11]. The majority
of this research has focused on building accurate classification
models from reduced sets of features. Some of these analyses also
aim to gain understanding of the differences between normal and
malignant cells and to identify genes that are differentially
regulated during cancer development. The importance of the
validity and reproducibility of statistical analysis and reporting
cannot be stressed enough [12].
Typically, a gene expression data set may consist of dozens of
samples but with thousands or even a few tens of thousands of
genes (acting as features, using the ML terminology). Predictive
model construction using this very high ratio between number of
features and number of samples is a delicate undertaking, prone to
obtain unreliable readings. As a result, dimensionality reduction
and in particular feature selection techniques may be very useful, as a
way to reduce the problem complexity and lighten medical expert
diagnosis.
Of special importance in a practical medical setting is the
interpretability of the obtained solutions, something that limits the
applicability of methods such as PCA or ICA (whose solutions
involve weighted combinations of genes, instead of individual
genes). Moreover, in a medical context, data visualization in a low-
dimensional representation space may become extremely important,
as it would help doctors to gain insights into this complex and
highly sensitive domain. The development of predictive models
able to discern between healthy and FSHD samples with minimal
error rate and amenable to direct interpretation is thus a clear
research goal. When predictive models use very low numbers of
relevant genes, these genes are likely to be associated with the
disease, and can be used as a starting mechanism for further
dedicated study from a biological point of view.
The present study addresses all these issues in two FSHD
databases (named, just for reference in this paper, as FSHD-DB1
and FSHD-DB2) to discern between healthy and FSHD samples
(clinical cases). We report experimental results supporting the
practical advantage of combining robust feature selection and
classification in the analyzed FSHD datasets. The described
method is able to unveil two groups of genes that yield very low
mean cross-validation error. These genes can be used to build very
simple decision procedures in the form of a decision tree.
Results and Discussion
FSHD-DB1 Database
The feature selection process in Algorithm 1 comes to a final
solution in the form of a subset with only three genes and a 100%
of mean 565 cv accuracy. This final subset is presented in Table 1
including its gene IDs and full names. It will be hereafter referred
as the FSHD-DB1 model. In comparison, PAMR delivers a 96.8%
of mean 565 cv accuracy with 2 genes (Table 2), and SVM-RFE
delivers a comparable 99.4% mean 565 cv accuracy, using 5
genes (Table 3). As a further comparison, if we consider the two
genes signaled as most relevant in the literature (DUX4 [7] and
FRG1 [13]), the corresponding mean 565 cv accuracy of these two
genes (taken together) is 84.65%.
Visualization. Data visualization in a low-dimensional rep-
resentation space is extremely important to gain a better
understanding of the solution delivered by the process. To
visualize the result, the data corresponding to the FSHD-DB1
model are plotted using the three selected genes as axes, without
any pre-processing method or projection technique –Fig. 1. In
addition, the LDA decision boundary fitted in the whole data set is
shown. The FSHD group presents a less compact distribution,
while the Healthy group is clustered around a specific region of the
representation space given by the three genes found. It can be seen
that the two conditions are neatly separated.
Figure 2 shows a box plot for each gene in the FSHD-DB1
model. LAMP1 shows a mean value for FSHD samples of
2087:90+157:04, against Healthy with mean 1092:91+54:41;
DPF3 shows a more even expression level, FSHD with
1005:78+83:79 and Healthy with 881:93+40:73; KPNA2 tends
to up-regulate heavily in FSHD (mean 788:81+78:92, compared
to Healthy with 305:92+23:59).
Figure 3 depicts a dendrogram of cases and standardized gene
expression levels for the FSHD-DB1 model. Each case is identified
with an ID number, prefixed by a letter indicating class
membership, H for Healthy and F for FSHD. It is apparent that
LAMP1 shows an up-regulation in most of the FSHD cases, as well
as KPNA2; DPF3 shows a slightly diffuse expression level.
Nonetheless, it is noticed in Fig. 3 that the natural clusters do
not necessarily correspond to labeled samples, and thus supervised
information is needed to create accurate prediction models, even
in this low-dimensional representation. Three clusters are discov-
ered: a first one (H1 to H17), in which most (but certainly not all)
of the samples belong to Healthy class; a second group (H18 to
H22), containing three Healthy and two FSHD samples; finally, a
third group (from F23 on) which is completely messed up. This
result –although is certainly dependent on the limitations of
clustering methods– alerts against using unsupervised feature
extraction methods like PCA.
An interesting point to be emphasized in these graphic
representations is that the FSHD-DB1 model clearly clusters the
two conditions neatly –Fig. 1. We were therefore interested in
ascertaining to what extent is this result stable and may thus
constitute a good departing point for future studies. To this end,
we performed two further investigations:
Table 1. Best gene subset found using the proposed method
and LDA as performance measure in FSHD-DB1 (the FSHD-
DB1 model).
Probe set ID Gene Name
201088_at KPNA2 karyopherin alpha 2 (RAG cohort
1, importin alpha 1)
219746_at DPF3 D4, zinc and double PHD fingers,
family 3
201552_at LAMP1 lysosomal-associated membrane
protein 1
doi:10.1371/journal.pone.0082071.t001
Table 2. Best gene subset found using PAMR in FSHD-DB1.
Probe set ID Gene Name
218959_at HOXC10 homeobox C10
215000_s_at FEZ2 fasciculation and elongation protein
zeta 2 (zygin II)
doi:10.1371/journal.pone.0082071.t002
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1. The first action was to change the resampling method to 10
times 10-fold cross validation (10610 cv). This form of
resampling entails a much higher computational cost; however,
it has been suggested as adequate for small sample situations
[14].
2. The second action was to analyze the statistical differences
between FSHD vs. Healthy samples in the expression levels for
the genes in the model. In addition, we explored the possibility
that a single gene is able to (almost) perfectly separate the two
classes by mere chance.
Statistical analysis. We were interested in exploring the
effect of changing the resampling method, keeping the same
classifier (LDA in this case), in order to exclude this source of
variation from the analysis. Remarkably, using 10610 cv instead
of 565 cv in Algorithm 1, it was found that the final result fully
coincided with the FSHD-DB1 model.
In order to assess statistical significance of expression levels, the
Mann-Whitney U-test (MWU) was used in the comparison
between FSHD vs. Healthy samples in the model. This is a non-
parametric hypothesis test for assessing whether one of the two
conditions (FSHD in this case) tends to have larger values than the
other.
For KPNA2, medians for the two groups Healthy and FSHD
were 307:41 and 736:98; the distributions in the two groups
differed significantly (Mann-Whitney W= 243, p-value
2:06:10{7).
For DPF3, medians for the two groups Healthy and FSHD were
888:61 and 867:44; the distributions in the two groups did not
differed significantly (Mann-Whitney W= 150, p-value 0:1886).
For LAMP1, medians for the two groups Healthy and FSHD
were 1088:76 and 2000:11; the distributions in the two groups
differed significantly (Mann-Whitney W= 243, p-value
2:06:10{7).
Therefore both KPNA2 and LAMP1 genes present high
differences in the two conditions. Although these two genes are
not equal, they present notable similarities. Spearman’s rank
correlation coefficient is equal to 0:771. This fact will be used to
simplify the FSHD-DB1 model.
One may still wonder about the probability of finding such a
single gene like KPNA2–that separates the two conditions with one
exception– by mere chance (Fig. 2). If a gene bears no relation
with the disease, we could expect an arbitrary pattern for the
distribution of the two conditions (healthy vs. FSHD cases) across
the expressed values of the gene. The probability that one or more
genes in 22,283 separates the two conditions (14 FSHD; 18
healthy) with only one exception is found to be around 7:9:10{4.
A final interpretable model. Even though the LDA
decision boundary in Fig. 1 depicts a clean separation between
the two patient conditions, its application as a decision tool may
not be straightforward. In this sense, decision trees are one of the
preferred tools by experts in decision making processes. Moreover,
the final selection of a gene subset may still provide few clues about
the structure of the two conditions with respect to their expression
levels. Some accuracy may be sacrificed for increased interpret-
ability of the model.
Figure 4 shows a CART decision tree [15] built with the FSHD-
DB1 model. The main question is on the expression level of gene
KPNA2: the right branch corresponds to 13 (all but one) of the
FSHD patients; the left branch corresponds to all of the 18 healthy
ones plus the remaining FSHD patient. Moreover, one may
wonder if there is a second gene, expressed such that it separates
this specific patient from the 18 healthy ones, and indeed there is
one: precisely DPF3. Whether this last patient is an outlier in a
medical sense we cannot know, but it deserves further clinical
Table 3. Best gene subset found using SVM-RFE in FSHD-DB1.
Probe set ID Gene Name
202594_at LEPROTL1 leptin receptor overlapping transcript-like 1
208065_at ST8SIA3 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3
209797_at CNPY2 canopy 2 homolog (zebrafish)
215000_s_at FEZ2 fasciculation and elongation protein zeta 2 (zygin II)
218959_at HOXC10 homeobox C10
doi:10.1371/journal.pone.0082071.t003
Figure 1. LDA decision surface for the FSHD-DB1 model.
doi:10.1371/journal.pone.0082071.g001
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investigation. Therefore, despite LAMP1 shows a markedly
differential expression, it may be excluded from the decision flow.
Biological evidence. In this section, we compile scientific
knowledge about the two genes in the final subset, including their
known primary functions in cellular process.
KPNA2. KPNA2 is Karyopherin alpha 2 (RAG cohort 1,
importin alpha 1). It is known that muscle functions are dependent
on spatial and temporal control of gene expressions in myofibers.
These are multinucleated cells that contain hundreds of nuclei
spread across the length of the cell in a common cytoplasm. Their
very important role is to control the transcriptional activity of
several nuclei in a common cytoplasm [16].
Analyzing the role of karyopherin alpha (KPNA) and paralogs-
specific roles of KPNA1 and KPNA2 during myogenesis, it has been
found that these two genes do regulate myoblast proliferation.
Particularly, KPNA2 regulates myotube size and myocyte migra-
tion [17]. Therefore, both may be involved in the nuclear
transport of proteins [18], which has a key role in controlling gene
expression in skeletal muscles.
DPF3. DPF3 is D4, zinc and double PHD fingers, family 3.
This gene belongs to the neuron-specific chromatin remodeling
complex (nBAF complex), acting as a tissue-specific anchor
between histone acetylations and methylations and chromatin
remodeling [18,19]. Experiments in human cardiac samples and
mouse embryonic and adult hearts showed that it plays a role in
heart and skeletal muscle development [20]. It also presents an up-
regulated expression in patients with Tetralogy of Fallot, a congenital
heart defect, partially characterized by muscular hypertrophy.
FSHD-DB2 Database
The feature selection process in Algorithm 1 comes to a final
solution with six genes and 99.6% of mean 565 cv accuracy. This
final subset is presented in Table 4 including its gene IDs and full
names (of which two of them are yet unknown). It will be hereafter
referred as the FSHD-DB2 model. In comparison, PAMR delivers
a 70.4% of mean 565 cv accuracy with 3 genes (Table 5), and
SVM-RFE delivers 85.2% mean 565 cv accuracy, using 5 genes
(Table 6, of which three of them are unknown). This database
Figure 2. Box plots for the expression levels of the genes in the FSHD-DB1 model.
doi:10.1371/journal.pone.0082071.g002
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contains DUX4 entries, corresponding to 4 isoforms. If we consider
the most informative model, including the 4 sequences of DUX4
and FRG1 together, the corresponding 565 cv accuracy is found
to be a disappointing 39.60%.
Visualization. Figure 5 shows a box plot for each gene in
the FSHD-DB2 model. The first three genes in the model
(Unknown-7905039, GDNF and EXTL1) tend to up-regulate
heavily, this time in Healthy samples. The other three seem to
contain complementary information in the variance rather than in
the central tendency. Figure 6 depicts a dendrogram of cases and
standardized gene expression levels for the FSHD-DB2 model.
Each case is identified with an ID number, prefixed by a letter
Figure 3. Clustering of the expression levels of the genes in the FSHD-DB1 model. Left: by genes; Top: by samples.
doi:10.1371/journal.pone.0082071.g003
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indicating class membership, H for Healthy and F for FSHD. It is
apparent that the natural clusters are less homogeneous than those
obtained for the FSHD-DB1 database. Nonetheless, the group of
central clusters (formed only by Healthy cases, H4 to H36) is
clearly identified by GDNF and EXTL1, both genes showing a
definite up-regulation in all cases.
Statistical analysis. Again, statistical significance of individ-
ual expression levels in the FSHD-DB2 model is assessed with a
Mann-Whitney U-test (MWU) in the comparison between FSHD
vs. Healthy samples.
For Unknown-7905039, medians for the two groups (FSHD and
Healthy) were 2:41 and 2:62, resp.; the distributions in the two
groups differed significantly (MannWhitney W= 118, p-value
9:22:10{5).
For GDNF, medians for the two groups (FSHD and Healthy)
were 6:76 and 7:22, resp.; the distributions in the two groups
differed significantly (MannWhitney W= 114, p-value 6:32:10{5).
For EXTL1, medians for the two groups (FSHD and Healthy)
were 6:98 and 7:26, resp.; the distributions in the two groups
differed significantly (MannWhitney W= 96, p-value 9:90:10{6).
For the other three genes, the medians for the two groups are
very close and the test is non-significant at the 95% level. This
seems to confirm the previous interpretation of a first subgroup of
three genes (Unknown-7905039, GDNF and EXTL1) that contain
highly discriminant information in their means (or medians) and a
second subgroup of another three genes (RPL36AP40, IGHMBP2
and Unknown-8147750) that complement the first group. Interest-
ingly, this split fully coincides with the order in which the genes
were discovered by the feature selection process in Algorithm 1.
The second-ranked gene, GDNF, is also chosen by the PAMR
method (Table 5).
In contrast to the previous database, the genes in the FSHD-
DB2 model seem quite different and, this time, no single gene can
separate the two conditions neatly; rather, they collaborate to
reach a very high classification accuracy. Indeeed, the absolute
value of Spearman’s rank correlation coefficient is lower than 0.5
in all cases, and specially low in the first subgroup of relevant
genes.
A final interpretable model. As for the previous database,
accuracy may be sacrificed for increased interpretability of the
model. Figure 7 shows a CART decision tree built with the FSHD-
DB2 model. The interpretation of the tree is as follows: patients
showing a value of GDNF lower than 6.8 are all classified
(correctly) as having the FSHD condition, and this group
constitutes 28% of the total; patients showing a value of GDNF
greater than 6.8 and a value of EXTL1 greater than 7.2 are all
classified (correctly) as not having the FSHD condition, and this
group constitutes 34% of the total; for the final group (38% of the
total), 12 patients are correctly identified as having the FSHD
condition, and the remaining 7 are incorrectly identified as having
the FSHD condition; thus the tree makes 7 false positives and no
false negatives.
Biological evidence. In this section, we compile scientific
knowledge about the two genes in the final subset, including their
known primary functions in cellular process.
GDNF. GDNF is glial cell derived neurotrophic factor: a gene
encoding a highly conserved neurotrophic factor. The recombi-
nant form of the protein has been shown to promote the survival
and differentiation of dopaminergic neurons in culture, and is able
to prevent apoptosis of motor neurons induced by axotomy [18].
GDNF is also associated to the Hirschsprung disease (HSCR), a
congenital disorder typically characterised by a part or all of the
large intestine having no nerves and intestinal obstruction, due to
an absence of intramural ganglia along the intestine [21].
EXTL1. EXTL1 is exostoses (multiple)-like 1. This gene is a
member of the multiple exostoses (EXT) family of glycosyltrans-
ferases. The encoded protein is involved in chain elongation of
some acidic complex polysaccharides found on the cell surface and
Figure 4. Classification tree for the simplified model in the
FSHD-DB1 database. The boxes are leaves indicating the prediction,
the numbers of cases for each condition, and the overall percentage of
covered cases.
doi:10.1371/journal.pone.0082071.g004
Table 4. Best gene subset found using the proposed method
and LDA as performance measure in FSHD-DB2 (the FSHD-
DB2 model).
Probe set ID Gene Name
7905039 Unknown
8111670 GDNF glial cell derived neurotrophic factor
7899075 EXTL1 exostoses (multiple)-like 1
7947152 RPL36AP40 ribosomal protein L36a pseudogene 40
7942073 IGHMBP2 immunoglobulin mu binding protein 2
8147750 Unknown
doi:10.1371/journal.pone.0082071.t004
Table 5. Best gene subset found using PAMR in FSHD-DB2.
Probe set ID Gene Name
8111892 OXCT1 3-oxoacid CoA transferase 1
8062461 LBP lipopolysaccharide binding protein
8111670 GDNF glial cell derived neurotrophic factor
doi:10.1371/journal.pone.0082071.t005
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Table 6. Best gene subset found using SVM-RFE in FSHD-DB2.
Probe set ID Gene Name
7893282 Unknown
8129666 SLC2A12 solute carrier family 2 (facilitated glucose transporter), member 12
7926818 Unknown
8094938 NIPAL1 NIPA-like domain containing 1
7938667 Unknown glial cell derived neurotrophic factor
doi:10.1371/journal.pone.0082071.t006
Figure 5. Box plots for the expression levels of the genes in the FSHD-DB2 model.
doi:10.1371/journal.pone.0082071.g005
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Figure 6. Clustering of the expression levels of the genes in the FSHD-DB2 model. Left: by genes; Top: by samples.
doi:10.1371/journal.pone.0082071.g006
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in the extracellular matrix [18]. Mutation in EXT1 is associated
with hereditary multiple exostoses, a human disorder character-
ized by the formation of cartilage-capped bony outgrowths at the
epiphyseal growth plates [22].
Concluding Remarks
The Facioscapulohumeral Muscular Dystrophy, or FSHD, is a
highly rare muscle disease for which there is no known cure
nowadays. Two databases presenting samples of both healthy and
FSHD patients have been analyzed with machine learning (ML)
methods. There is hardly any precedent in the literature
addressing this disease with these techniques.
The fact that the FSHD data analyzed in this study are scarce
and of high dimensionality makes their computer-based automat-
ed classification a difficult undertaking. Most importantly, this
high dimensionality precludes a straightforward interpretation of
the obtained results, limiting their usability in a practical medical
setting. In this vein, computational solutions like the one reported
here should reckon the need of reporting not only highly accurate
models: they should also represent low complexity and interpret-
able solutions amenable to further analysis by experts.
We have devised an approach to prediction of the FSHD
condition from gene expression profiling, comprising an effective
algorithm for gene selection enhanced with a mechanism for tie-
breaking and based on a fairly standard classifier. To demonstrate
its effectiveness, we show that the method was highly efficient in
identifying two subsets of genes that best characterize each class.
In both cases, the discrimination process is shown very
conveniently as a two-question decision tree. We have also
provided evidence for the statistical significance and stability of the
result. Our method delivers highly interpretable solutions that are
more accurate than competing methods. The technique is general
and could be used in other similar scenarios.
However, in small sample scenarios, there is a high risk of
overfitting the data: small samples will appropriately support only
simple models with few parameters (acting as the coefficients of the
features). Moreover, the use of a classifier having one or more
hyper-parameters (these are parameters that the classifier cannot
determine in its training process, and must be determined
externally) is unaffordable, since this would require an additional
resampling loop, for which there would almost be no data left. As a
consequence, the determination of these parameters would be
subject to a very high degree of uncertainty. We have selected
Linear Discriminant Analysis (LDA) as the target classifier, using
equal-covariance Gaussians to approximate class conditional
probability densities. This choice corresponds to a linear, stable
and parameter-free classifier. The LDA recognition rate was
resampled using 5 times 5-fold cross validation.
One should bear in mind that the excellent reported results do
not –by themselves– entail a medical solution to the disease, a
situation that is faced by all statistical and ML solutions. On the
contrary, a main goal of exploratory studies of this kind should be
aimed towards understanding how the variables selected by the
model fit in relation to prior knowledge from the medical domain.
Materials and Methods
The FSHD Databases
The first database used in this contribution was obtained from
the EMBL-EBI repository of the European Bioinformatics
Institute [23]. Specifically, the Experiment E-GEOD-3307 uses the
Affymetrix GeneChip Human Genome HG-133A and HG-
U133B designs to analyse a range of muscle diseases for gene
expression comparative profiling purposes. A total of 121 muscle
samples of 11 muscle pathologies (plus several healthy samples)
integrate the data: acute quadriplegic myopathy, juvenile derma-
tomyositis, amyotophic lateral sclerosis, spastic paraplegia, fascios-
capulohumeral muscular dystrophy, Emery Dreifuss muscular
dystrophy, Becker muscular dystrophy, Duchenne muscular
dystrophy, calpain 3, dysferlin, and the FKRP using U133A and
U133B array design. These are diseases with a extremely low
incidence rate in the general population. The Facioscapulohu-
meral Muscular Dystrophy (FSHD), the targeted group in this
work, consists of 14 FSHD samples and 18 healthy samples
described by 22,283 genes or features (HG-133A version).
The second database was obtained from the GEO (Gene
Expression Omnibus) repository, a publicly available site in the
National Center for Biotechnology Information (NCBI). The
Experiment GSE36398, ‘‘Transcriptional profiling in facioscapulo-
humeral muscular dystrophy to identify candidate biomarkers’’ is a
very recent database containing FSHD information only. Using
the Affymetrix Human Gene 1.0 ST Array, the experiment
analyses RNA extracted from both biceps and deltoids of FSHD
subjects (26 samples) and unaffected first-degree relatives (24
samples), rendering a dataset that consists of 50 samples, described
by 33,297 genes or features [24].
There are no missing data in any of the two datasets; and both
contain a mixture of positive and negative examples, necessary for
learning. Moreover, in both cases the whole datasets were used.
Linear Discriminant Analysis
Linear and quadratic discriminant analyses or LDA/QDA
(Duda et al. 2001) are widely used parametric methods which
assume that the class distributions are multivariate Gaussians.
With LDA, all classes are assumed to have the same covariance
Figure 7. Classification tree for the simplified model in the
FSHD-DB2 database. The boxes are leaves indicating the prediction,
the numbers of cases for each condition, and the overall percentage of
covered cases.
doi:10.1371/journal.pone.0082071.g007
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matrix. QDA does not need such an assumption; however, the
number of parameters to be estimated from the data available for
each class is much higher, entailing lower statistical significance.
In both methods, classification is achieved by assigning an
example to the class for which the posterior probability P(vkj x )
is greater, or equivalently for which lnfP(vk)p( x jvk)g is
greater.
These methods are attractive because they need no parameter
tuning, and their limited complexity (quadratic at most) may be a
solid guard against overfitting the data. Moreover, for LDA fast
updating procedures exist for the computation of certain forms of
the cross-validation error [25]. The discriminant function for class vk
is expressed as:
gk(x)~ ln fP(vk)p(xjvk)g
~ ln P(vk){ ln f(2p)
n
2jSkj
1
2g{ 1
2
(x{mk)
tS{1k (x{mk)
which simplifies to:
gk(x)~ ln P(vk){
1
2
ln jSkjz(x{mk)tS{1k (x{mk)
 
If we assume that all class-conditional distributions p(xjvk) have
the same covariance matrix S, we get:
gk(x)~ ln P(vk)zm
t
kS
{1x{
1
2
m tkS
{1mk
These are linear discriminant functions (linear in x) and
the decision boundaries gi(x)~gj(x) are hyperplanes in n-
dimensional space.
In practical situations, only an i.i.d data sample S is available.
When means, covariances and priors for every class are not
available, maximum-likelihood estimates on S can be used,
although in this case the Bayesian optimality properties are no
longer valid. Let Sk5S be the subset of samples known to belong
to class vk. Then S1, . . . ,Sc is a partition of S. Unbiased estimates
for the vector means and for the class priors can be obtained as:
m k& m^ k~
1
jSkj
X
x [Sk
x ; P(vk)&P^(vk)~
jSkj
jSj
The following pooled covariance matrix is then used:
S&S^pooled~
1
jSj{c
Xc
k~1
(jSkj{1)S^k
where
S^k~
1
jSkj{1
X
x [Sk
(x{ m^k)(x{ m^k)
t
Linear Support Vector Machines
The support vector machine (SVM) is a machine learning
method solidly based on statistical learning theory [26]. Intuitively,
given a set of examples labeled into one of two classes, the linear
SVM finds their optimal linear separation: this is the hyperplane
that maximizes the minimum orthogonal distance to a point of
either class (this distance is called margin of the separation).
Consider again an i.i.d data sample S~fx1, . . . ,xNg of training
patterns (in n dimensions), labelled into two classes v1,v2 by
z1, . . . ,zN , with zi~z1 if x i[v1 and zi~{1 if x i[v2. If we
set up an affine function g(x)~Sw,xTzb, then we have a linear
discriminant as sgn(g( x )), for which we would like:
Sw ,xiTzbw0 x i[v1 (zi~z1)
Sw ,xiTzbv0 x i[v2 (zi~{1)
In short, zi(Sw,xiTzb)w0, or zig(xi)w0, for all 1ƒiƒN.
Given the hyperplane p : g(x)~0, the perpendicular distance
from x to p is d(x ,p)~
jg(x)j
EwE
. The support vectors are those x
closest to the hyperplane. Rescaling w,b such that jSw,xTzbj~1
for these closest points, one obtains jSw,xTzbj§1. The support
vectors are now those fxi=jSw,xiTzbj~1g.
The margin m(p) of a plane p can now be written as twice its
distance of any support vector: m(p)~2d(xSV,p)~
2
EwE
, where
jg(xSV)j~1. To maximize the margin, we should minimize EwE
subject to zi(Sw,xiTzb)§1, for all 1ƒiƒN.
In the case where an hyperplane does not exist that can separate
correctly the points in the data sample, a set of non-negative slack
variables are introduced to allow for small margin violations, leading
to a soft margin:
zi(Sw ,xiTzb)zji§1 i~1, . . . ,N ð1Þ
where ji§0. For an error to occur, the corresponding ji must
exceed unity, and so
P
i ji is an upper bound on the number of
training errors. The optimal separating hyperplane can be found as
the solution of the 1-norm Quadratic Programming problem:
min
w ,j
1
2
jj w jj2zC
XN
i~1
ji
s:t: zi(Sw ,xiTzb)§1{ji,i~1, . . . ,N
The solution to this optimization problem corresponds to the
saddle point of its associated Lagrangian:
jjw jj2
2
{
XN
i~1
ai(zi(Sw ,xiTzb){1zji)zC
XN
i~1
ji{
XN
i~1
miji
where ai,mi§0 for i~1, . . . ,N.
Once this QP problem is solved, the solution vector w can be
expressed as a linear expansion over the support vectors:
w ~
XN
i~1
ai zi x i ð2Þ
The support vectors are precisely those x i[S for which aiw0.
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Resampling Methods
Model selection is concerned with the process of finding the
optimal model for a set of samples among a set of candidate
models. Resampling methods aim at making a better use of the
available data. These methods are very useful for assessing how a
predictive model that can be the result of a complex modeling
process will perform in practice.
The generic goal of cross-validation (CV) is to estimate the
expected error of a model in a data set that is independent of the
data that were used to train the model. One round of k-fold CV
(or k-CV) involves partitioning the sample into k complementary
subsets, systematically performing the modeling on the union of
k{1 such subsets and checking the obtained model on the
remaining subset (acting as a validation set). The result of k-CV is
an estimation of the error if only a fraction (k{1)=k of the
available data is used. This error is expected to be conservative
(larger than the error obtained if the entire sample was used). To
reduce variability, multiple rounds can be performed using
different partitions, and the results averaged over the rounds.
The Feature Selection Algorithm
Feature selection can be seen as a search problem, where each
state in the search space corresponds to a subset of the features. In
the ML literature, a wide family of suboptimal algorithms depart
from an initial solution and iteratively add or delete features by
locally optimizing the error function. In forward selection, features
are progressively incorporated into larger subsets; in backward
selection (or elimination) one starts with the full set of features and
progressively eliminates elements from it.
Wrappers are often criticized because they are computationally
very expensive. Moreover, feature selection is badly affected by
small sample sizes, producing overly optimistic results and
introducing an excess of variance in the readings. This is
aggravated in the presence of very sophisticated search algorithms
[27]. On the other hand, greedy search strategies seem to be
particularly computationally advantageous and may alleviate the
problem of overfitting [28]. Nevertheless, traditional pure for-
wardd selection and backward elimination search algorithms are
ill-advised in that they cannot rectify their decisions and may end
up delivering poor solutions both in terms of quality and size.
To reduce the number of genes and obtain small subsets of
highly relevant genes, we use a simple but effective forward-
backward feature selection algorithm. This algorithm follows the
wrapper idea, i.e., the feature selection algorithm uses a learner as
a subroutine in the search for good subsets [29]. In this general
setting, when features are added or removed from the current
subset the algorithm resorts to some performance measure –
commonly the resampled rate of recognition.
An interleaved forward-backward search is developed looking
for the improvement in performance of the chosen performance
measure. The algorithm is described as the listing Algorithm 1.
Given a performance measure L to be maximized (in this case, the
resampled evaluation of a classifier in a data sample), the
algorithm searches the space of subsets by adding/removing
features in a hill-climbing fashion.
Specifically, in every iteration of the outer loop, one feature is
added to the current best solution BEST , as long as this step
improves on current performance Lcur. Then a variable number of
feature removal steps is carried out, inasmuch the same condition
of improved performance is met. This scheme is oriented to favour
solutions with low numbers of features. The outer iteration also
ends when no further improvement is observed. This strategy
bears some resemblances with a floating search algorithm in its
forward version [30]. However, it has a far lower computational
cost given that discarded features are not considered again for
another inclusion round. Note also that current subset perfor-
mance is not compared specifically against the best performance
achieved for the same size of the current subset (as floating methods
do). It should be mentioned that the algorithm itself needs no
parameter specification, although the chosen performance mea-
sure could have.
Algorithm 1 Forward-Backward gene feature selection.
1: Input: S~fs1, . . . ,sng: Full feature set;
C: Class feature (Healthy, FSHD)
L : 2S?R: performance measure, to be maximized
2: BEST/ arg
max
si[S
L(fsig)
3: Lcur/L(fBESTg)
4: S/S\fBESTg
5: repeat
6: ***Forward Stage***
7: snew/ arg
max
si[S
L(BEST|fsig)
8: Lnew/L(BEST|fsnewg)
9: if LnewwLcur then.
10: BEST/BEST|fsnewg
11: Lcur/Lnew
12: S/S\fsnewg
13: end if
14: ***Backward Stage***
15: repeat
16: snew/ arg
max
si[BEST
L(BEST\fsig)
17: Lnew/L(BEST\fsnewg)
18: if Lnew§Lcur then
19: BEST/BEST\fsnewg
20: Lcur/Lnew
21: end if
22: until BEST does not change
23: until BEST does not change
24: Output: BEST: Optimized feature subset
As explained in the introduction, we are interested in a solution
that combines high predictive performance, very small size (i.e., a
very low number of useful genes), admits visualization and
interpretation, and hopefully may bear biological relevance.
To this end, we explicit now how the methods previously
described glue together. The performance measure L to be
maximized in Algorithm 1 is the accuracy rate of LDA. This
recognition rate is resampled using 5 times 5-fold cross validation
(565 cv for short), following common practices in the literature
[31].
Due to the low number of samples, ties among the performance
measure can happen easily. As a consequence, the gene subset
selection process will end up in different final solutions, something
that is not desirable in general [32]. How these ties are broken is
non-trivial and should be addressed specifically and explicitly.
However, the literature does not seem to offer any formal solution
or procedure. Univariate methods as entropy-based measures
[33,34], the Fisher Score [35], or some other statistical measures
could be those preferred for their simplicity –see e.g. [36,37].
Instead, a multivariate feature ranking method seems much more
adequate to measure the relevance of a group of tied features.
As explained above, linear support vector machines (SVMs) can
be seen as linear discriminant classifiers. Indeed, the numbers
(wi )
2 in eq. (2) have been used as a surrogate for the relevance of
the i-th gene since the pioneering work of [38]. Notice that our
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approach is different in that predictive performance is the main
criterion for optimization. Only in case of ties is the magnitude of
the SVM weight vector being used. This is because the relation
between this magnitude and final performance is rather indirect.
This margin-based tie-breaking procedure has been incorporated
into the feature selection algorithm. It is used every time an
evaluation of the performance measure may incur on one or more
ties –lines 2,7 and 16 in Algorithm 1.
Other Methods
Prediction analysis for microarrays. PAMR (Prediction
Analysis for Microarrays) performs sample classification from gene
expression data, via the nearest shrunken centroid method [39].
Similarly to the proposed method, PAMR estimates prediction
error via cross-validation and provides a list of significant genes
whose expression characterizes each diagnostic class.
Support vector machine for recursive feature
elimination. SVM-RFE (Support Vector Machine - Recursive
Feature Elimination) [38] has been used widely with great success
in microarray data analysis, particularly for disease gene finding. It
largely eliminates redundant genes and usually yields very
compact gene subsets. The genes are eliminated according to a
ranking related to weight magnitude in the SVM solution. This is
the same criterion for tie-breaking described in the previous
section.
Software Implementation
Algorithm 1 was implemented entirely in MATLAB language,
version 2012a. The computer codes were run on an Ubuntu Linux
server version 11.10 with an Intel(R) Xeon(R) CPU E5620 @
2.40 GHz and 8 cores. The deployed solution to Algorithm 1
takes advantage of the possibility to parallelize parts of the code,
particularly lines 2, 7 and 16. In an 8-core scenario, eight genes or
features can be evaluated at the same time. The complete software
and instructions to reproduce the experiments described in this
paper (or to conduct new ones) is available at http://nova.mxl.
uabc.mx/fernando/PO/for the interested reader.
The LDA classification algorithm and the resampling methods
implied in Algorithm 1 are developed using already existing
MATLAB functions. The only part that uses an external toolbox is
in the tie-breaking procedure –eq. (2). The well-known Steve
Gunn’s MATLAB Support Vector Machine Toolbox [40] was
used for this purpose. Full specification of parameters is described
in the url link given above.
It is important to clarify that the data sets were used without any
pre-processing step. The learning algorithms and the complete
experimental setting were fed with the original downloaded E-
GEOD-3307 and GSE36398 data. Complete details about the E-
GEOD-3307 data set can be found at http://www.ebi.ac.uk/
arrayexpress/experiments/E-GEOD-3307/and for GSE36398
data set, the location is http://0-www.ncbi.nlm.nih.gov.elis.tmu.
edu.tw/sites/GDSbrowser?acc =GDS4404. The two datasets
differ in the number of columns given that they correspond to
different technologies or gene chip versions. Although it is possible
to map genes from one technology to another, this process requires
a considerable effort that goes beyond the scope of this paper.
The PAMR experiments were conducted through a specific R
implementation [39] and run on the same Ubuntu Linux server
described above. Specifically, the Nearest Shrunken Centroid
classification algorithm works by shrinking each of the class
centroids toward the overall centroid by a certain amount called
the threshold. We used an adaptive computation of this value as
provided in the PAMR package.
The SVM-RFE experiments were implemented with the Spider
v1.7 software, a MATLAB Machine Learning package popular for
feature selection tasks –see http://people.kyb.tuebingen.mpg.de/
spider/main.html.
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